Literature DB >> 3395278

Reduced atherogenesis in cholesterol-fed diabetic rabbits. Giant lipoproteins do not enter the arterial wall.

B G Nordestgaard1, S Stender, K Kjeldsen.   

Abstract

In cholesterol-fed rabbits, alloxan-diabetes has an anti-atherogenic effect, which is associated with severe elevation of plasma triglyceride concentrations. To study this effect, we measured lipoprotein sizes and aortic permeability coefficients for cholesteryl ester and for albumin in hypertriglyceridemic diabetic cholesterol-fed rabbits and in normotriglyceridemic cholesterol-fed rabbits. With the same high cholesterol concentration in plasma, hypertriglyceridemic diabetic rabbits had 70% of plasma cholesterol in very large lipoproteins (diameter greater than 75 nm), whereas normotriglyceridemic rabbits had only about 10% of plasma cholesterol in these giant lipoproteins. The aortic permeability coefficients for cholesteryl ester in hypertriglyceridemic diabetic cholesterol-fed rabbits was only 10% to 50% of that in normotriglyceridemic cholesterol-fed rabbits. Aortic permeability coefficients for albumin did not differ significantly between the hypertriglyceridemic and normotriglyceridemic rabbits. The results suggest that the large size of a major fraction of plasma lipoproteins in the hypertriglyceridemic diabetic cholesterol-fed rabbits is responsible for the relatively low aortic permeability coefficient for cholesteryl ester from plasma and hence for reduced atherogenesis in these animals.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3395278     DOI: 10.1161/01.atv.8.4.421

Source DB:  PubMed          Journal:  Arteriosclerosis        ISSN: 0276-5047


  30 in total

Review 1.  IDL, VLDL, chylomicrons and atherosclerosis.

Authors:  B G Nordestgaard; A Tybjaerg-Hansen
Journal:  Eur J Epidemiol       Date:  1992-05       Impact factor: 8.082

Review 2.  Atherosclerosis: Making a U Turn.

Authors:  Ira J Goldberg; Gaurav Sharma; Edward A Fisher
Journal:  Annu Rev Med       Date:  2020-01-27       Impact factor: 13.739

Review 3.  Postprandial hypertriglyceridemia and cardiovascular disease: current and future therapies.

Authors:  D C Chan; J Pang; G Romic; G F Watts
Journal:  Curr Atheroscler Rep       Date:  2013-03       Impact factor: 5.113

Review 4.  Lymphatic transport of high-density lipoproteins and chylomicrons.

Authors:  Gwendalyn J Randolph; Norman E Miller
Journal:  J Clin Invest       Date:  2014-03-03       Impact factor: 14.808

Review 5.  The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk.

Authors:  Pratik B Sandesara; Salim S Virani; Sergio Fazio; Michael D Shapiro
Journal:  Endocr Rev       Date:  2019-04-01       Impact factor: 19.871

6.  Deficiency of receptor-associated protein attenuates angiotensin II-induced atherosclerosis in hypercholesterolemic mice without influencing abdominal aortic aneurysms.

Authors:  Shaoping Wang; Venkateswaran Subramanian; Hong Lu; Deborah A Howatt; Jessica J Moorleghen; Richard Charnigo; Lisa A Cassis; Alan Daugherty
Journal:  Atherosclerosis       Date:  2011-11-19       Impact factor: 5.162

7.  Diabetes with poor glycaemic control does not promote atherosclerosis in genetically modified hypercholesterolaemic minipigs.

Authors:  Rozh H Al-Mashhadi; Martin M Bjørklund; Martin B Mortensen; Christina Christoffersen; Torben Larsen; Erling Falk; Jacob F Bentzon
Journal:  Diabetologia       Date:  2015-05-31       Impact factor: 10.122

Review 8.  Lipoprotein size and susceptibility to atherosclerosis--insights from genetically modified mouse models.

Authors:  Murielle M Véniant; Anne P Beigneux; André Bensadoun; Loren G Fong; Stephen G Young
Journal:  Curr Drug Targets       Date:  2008-03       Impact factor: 3.465

9.  Increased atherosclerosis in streptozotocin-induced diabetic mice.

Authors:  V V Kunjathoor; D L Wilson; R C LeBoeuf
Journal:  J Clin Invest       Date:  1996-04-01       Impact factor: 14.808

Review 10.  Advances in lipid-lowering therapy through gene-silencing technologies.

Authors:  Børge G Nordestgaard; Stephen J Nicholls; Anne Langsted; Kausik K Ray; Anne Tybjærg-Hansen
Journal:  Nat Rev Cardiol       Date:  2018-02-08       Impact factor: 32.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.